SANGAMO THERAPEUTICS, INC (SGMO) [Rocket]

Overview

SANGAMO THERAPEUTICS, INC (SGMO)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	SC 13G/A	WASATCH ADVISORS LP reports a 10.2% stake in Sangamo Therapeutics, Inc.
09/28/2023	4	BIOGEN INC. (10% Owner) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
08/15/2023	4	Willoughby Scott B. (SVP, Gen. Counsel & Secretary) has filed a Form 4 on SANGAMO THERAPEUTICS, INC
08/08/2023	S-8	Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/08/2023	8-K	Quarterly results
06/05/2023	4	Smith Karen L. (Director) has filed a Form 4 on SANGAMO THERAPEUTICS, INC

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	361.2	110.7	118.2	102.4	84.5	36.6	19.4	39.5
Revenue growth	226.3%	-6.3%	15.4%	21.3%	131.0%	88.6%	-51.0%	-13.8%
Cost of goods sold	499.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	-138.6	110.7	118.2	102.4	84.5	36.6	19.4	39.5
Gross margin	-38.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative
Research and development		230.8	180.6	145.9	114.9	65.7	65.6	67.2
General and administrative	62.7	63.2	67.1	61.7	46.7	27.2	26.3	19.2
EBIT	-201.3	-183.3	-129.6	-105.2	-77.2	-56.4	-72.6	-46.9
EBIT margin	-55.7%	-165.6%	-109.6%	-102.7%	-91.4%	-154.1%	-374.2%	-118.5%
Pre-tax income	-191.8	-178.0	-120.8	-95.4	-68.9	-54.6	-71.7	-46.4
Income taxes	0.4	0.3	0.3	0.0	0.0	0.0	0.0	-5.7
Tax rate				0.0%	0.0%	0.0%	0.0%	12.3%
Net income	-192.3	-178.3	-121.0	-95.2	-68.3	-54.6	-71.7	-40.7
Net margin	-53.2%	-161.1%	-102.4%	-92.9%	-80.9%	-149.2%	-369.6%	-102.9%

Diluted EPS	($1.25)	($1.23)	($0.90)	($0.85)	($0.70)	($0.70)	($1.02)	($0.58)
Shares outstanding (diluted)	153.8	144.6	134.4	112.1	96.9	78.1	70.6	69.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.